Clear Search sequence regions


  • 2A (9)
  • drug design (1)
  • humans (1)
  • mat2a protein, human (1)
  • MTAP (1)
  • protein human (1)
  • S (3)
  • Sizes of these terms reflect their relevance to your search.

    Methionine adenosyltransferase 2A (MAT2A) is a rate-limiting enzyme in the methionine cycle that primarily catalyzes the synthesis of S-adenosylmethionine (SAM) from methionine and adenosine triphosphate (ATP). MAT2A has been recognized as a therapeutic target for the treatment of cancers. Recently, a few MAT2A inhibitors have been reported, and three entered clinical trials to treat solid tumorsor lymphoma with MTAP loss. This review aims to summarize the current understanding of the roles of MAT2A in cancer and the discovery of MAT2A inhibitors. Furthermore, a perspective on the use of MAT2A inhibitors for the treatment of cancer is also discussed. We hope to provide guidance for future drug design and optimization via analysis of the binding modes of known MAT2A inhibitors.

    Citation

    Chunzheng Li, Gang Gui, Li Zhang, Anqi Qin, Chen Zhou, Xiaoming Zha. Overview of Methionine Adenosyltransferase 2A (MAT2A) as an Anticancer Target: Structure, Function, and Inhibitors. Journal of medicinal chemistry. 2022 Jul 28;65(14):9531-9547

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 35796517

    View Full Text